Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease
Authors' conclusion
A decentralised response-guided trial was feasible and safe
Study context
- Population
- Adults with T2D and chronic kidney disease (CKD), estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m², urinary albumin-to-creatinine ratio (UACR) > 4.5 mg/mmol (> 40 mg/g); mean age 69.6 yearscompleted the study
- Participants
- 11 adults
- Comparison
- Empagliflozin, then continued empagliflozin, add-on finerenone or substitution with finerenone guided by UACR response
- Empagliflozin-finerenone combinationn = 9
- Finerenone monotherapyn = 2
- Outcome
- Feasibility measures: participant-reported acceptability, sample delivery and completion of home measurements
Methodological detailsdecentralised response-guided trial, remote study procedures
- Decentralised response-guided trial
- Remote study procedures
Main finding
As reported in the abstract
Feasibility
Urine sample delivery rate
100%
Capillary blood sample delivery rate
98.8%
Home blood pressure completion rate
91.3%
Home body weight completion rate
98.6%
Further findings
Further UACR reduction relative to end of empagliflozin monotherapy (exploratory) · 4-week second treatment phase
UACR change during empagliflozin monotherapy (exploratory) · 3 weeks
- UACR change overall
- −18.7%
Safety
- Serious adverse events
- 0
- Hyperkalaemia events
- 0
Original publication
Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease. Diabetes Obes Metab. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →